Eisai (company)

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Bender the Bot (talk | contribs) at 12:24, 6 March 2017 (→‎Aricept: HTTP→HTTPS, per BRFA 8 using AWB). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Eisai Co., Ltd.
Native name
エーザイ株式会社
Company typePublic KK
TYO: 4523
TOPIX 100 Component
Nikkei 225 Component
IndustryPharmaceuticals
Founded(December 6, 1941; 82 years ago (1941-12-06))
FounderToyoji Naito
Headquarters4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088, Japan
Key people
Haruo Naito
(President and CEO)
Products
RevenueIncrease US$ 5.82 billion (FY 2013) (JPY 600.4 billion) (FY 2013)
Increase US$ 320 million (FY 2013) (JPY 33 billion) (FY 2013)
Number of employees
10,419 (consolidated, as of March 31, 2014)
WebsiteOfficial website
Footnotes / references
[1]

Eisai Co., Ltd. (エーザイ株式会社, Ēzai Kabushiki-gaisha) is a Japanese pharmaceutical company headquartered in Tokyo, Japan. It has some 10,000 employees, among them about 1,500 in research. Eisai is listed on the Tokyo Stock Exchange and is a member of the Topix 100 and Nikkei 225 stock indices.[2]

History

Nihon Eisai Co. Ltd. was established in 1941. In 1944, merger with Sakuragaoka Research Laboratory resulted in creation of Eisai Co. Ltd.[3] The American subsidiary of the company, Eisai Inc., was established in 1995.[4]

In 1996, Eisai received approval from the United States Food and Drug Administration (USFDA) for Aricept (donepezil), a drug discovered in the company's labs and co-marketed with Pfizer. Three years later in 1999, the company received USFDA approval for Aciphex (rabeprazole), a drug co-marketed with Johnson & Johnson.

In September 2006, the company acquired four oncology products from Ligand Pharmaceuticals.

In April 2007, Eisai acquired Exton, Pennsylvania-based Morphotek, a company developing therapeutic monoclonal antibodies for the treatment of cancer, rheumatoid arthritis, and infectious diseases.

In December 2007, Eisai acquired MGI Pharma, a company specializing in oncology, for $3.9 billion USD. This event brought Dacogen (decitabine), Aloxi (palonosetron), Hexalen (altretamine) for ovarian cancer, and the Gliadel Wafer (carmustine) for brain tumors into the Eisai product portfolio.

In 2009, Eisai received the Corporate Award from the National Organization for Rare Disorders (NORD) for the development of Banzel.[5]

Locations

Eisai head office in Tokyo

Eisai Co., Ltd. is based in Tokyo, Japan, while its American subsidiary Eisai Inc. is headquartered in Woodcliff Lake, New Jersey. Eisai maintains medical research headquarters in Woodcliff Lake, New Jersey as well as locations in Japan, the United Kingdom, the Research Triangle in North Carolina, and Massachusetts where the Eisai Research Institute and the Andover Innovative Medicines Institute are based.[6][7]

The company has manufacturing sites in Japan, North Carolina (USA), Maryland (USA), Bogor (Indonesia), Suzhou (China), Tainan (Taiwan), Visakhapatnam (India) and Hatfield, Hertfordshire (UK). Eisai has marketing operations in 19 European countries as well as the Asia-Pacific region.

Products

Some of the key products that Eisai produces or markets with partners include:

  • Aciphex/Pariet (rabeprazole) - Gastroesophageal reflux disease
  • Actonel (risedronic acid) - Osteoporosis (Japan)
  • Aloxi (palonosetron) - Chemotherapy-induced nausea and vomiting
  • Aricept (donepezil) - Mild to moderate dementia for Alzheimer's Disease patients
  • Banzel/Inovelon (rufinamide) - Seizures related to Lennox-Gastaut Syndrome
  • Belviq (lorcaserin) - Obesity
  • Fragmin (dalteparin) - Deep vein thrombosis and pulmonary embolism
  • Fycompa (perampanel) - Partial-onset seizures
  • Halaven (eribulin) - Metastatic breast cancer
  • Iomeron - Non-ionic contrast medium
  • Methylcobal - Peripheral neuropathy
  • Myonal - Muscle relaxant
  • Selbex - Gastric ulcers and gastritis
  • Zonegran (zonisamide) - Partial-onset seizures
  • Gliadel Wafer (carmustine)- Treatment for Brain Tumors
  • Lenvima (lenvatinib) - Thyroid Cancer or Kidney Cancer

Aricept

Aricept accounted for 40% of Eisai's revenue as of March 2010.[8] The main competitor to Aricept is a generic formulation from Ranbaxy Labs.[8] Eisai has pursued development of alternative formulations in order to extend the marketable lifetime of the product.[8]

See also

References

  1. ^ "Corporate Information". Eisai Co., Ltd. Retrieved February 9, 2015.[self-published source]
  2. ^ "Components:Nikkei Stock Average". Nihon Keizai Shimbun. Retrieved February 9, 2015.
  3. ^ Winograd, Claudia (October 16, 2007). "Eisai (Japan)". In Colditz, Graham A. (ed.). Encyclopedia of Cancer and Society. Sage Publications. doi:10.4135/9781412953979. ISBN 9781412949897. Retrieved February 9, 2015.
  4. ^ "Lonnel Coats Appointed President & Chief Executive Officer of Eisai Inc". Businesswire. Retrieved February 9, 2015.
  5. ^ "NORD to Honor Rare Disease Pioneers". PR Newswire. May 11, 2009. Archived from the original on February 9, 2015. Retrieved February 9, 2015.
  6. ^ Carroll, John (September 15, 2016). "Eisai launches biotech division in Massachusetts aimed at Alzheimer's, I/O and autoimmune diseases". Endpoint News. Retrieved November 4, 2016.
  7. ^ "Eisai Launches Facility to Advance Precision Medicine". News: Industry Watch. Genetic Engineering & Biotechnology News (Paper). October 15, 2016. p. 8.
  8. ^ a b c Kanoko Matsuyama (April 25, 2011). "Eisai Aricept Patch for Alzheimer's Isn't Ready for Approval". Bloomberg L.P. Retrieved April 25, 2011.

External links

Retrieved from "https://en.wikipedia.org/w/index.php?title=Eisai_(company)&oldid=768900557"